Barbara S. Craft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara S. Craft has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Pratap Singh
Department of Cell and Molecular Biology University of Mississippi Medical Center Jackson Mississippi USA
1 shared publication - Amod Sharma
Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
1 shared publication - Bibbin T. Paul
Department of Molecular Biology and Biophysics, University of Connecticut Health Center, Farmington, CT, USA
1 shared publication - Jasleen Kaur
Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
1 shared publication - Lavanya Challagundla
Department of Cell and Molecular Biology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA
1 shared publication - Sarabjeet Kour Sudan
Department of Cell and Molecular Biology University of Mississippi Medical Center Jackson Mississippi USA
1 shared publication
Latest Publications
- Open Access
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9680
Leptin-Driven Distinct Transcriptional Reprogramming in Triple-Negative Breast Cancer: Implications for Racial Disparities
Obesity is an established risk factor for breast cancer (BC), and leptin, an adipocyte-derived hormone, may link obesity to tumor progression. However, the role of leptin in the molecular heterogeneity of triple-negative breast cancer (TNBC), particularly across racial groups, remains unclear. Here, we examined circulating leptin levels in Black and White women with and without BC and characterized leptin-induced transcriptional changes in TNBC cell lines of White and Black racial backgrounds using RNA sequencing. Functional enrichment analyses were performed using Gene Ontology and KEGG pathway annotations, and clinical relevance was assessed using publicly available datasets. Circulating leptin levels were significantly elevated in women with BC and were relatively higher in Black than White women and associated with increased odds of luminal A and TNBC diagnoses. Leptin induced distinct transcriptional responses in two TNBC cell lines, with differential enrichment of oncogenic, metabolic, and signaling pathways, including spliceosome, steroid biosynthesis, PI3K-AKT, Notch, and extracellular matrix-receptor interaction. Several leptin-responsive genes showed concordant expression in clinical specimens and exhibited race- and subtype- associated differences and prognostic significance. Collectively, these findings identify distinct, context-dependent leptin-responsive transcriptional programs in TNBC and provide insight into their potential contributions to tumor heterogeneity and breast cancer disparities.
- 29 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9680
Open AccessLeptin-Driven Distinct Transcriptional Reprogramming in Triple-Negative Breast Cancer: Implications for Racial Disparities
Obesity is an established risk factor for breast cancer (BC), and leptin, an adipocyte-derived hormone, may link obesity to tumor progression. However, the role of leptin in the molecular heterogeneity of triple-negative breast cancer (TNBC), particularly across racial groups, remains unclear. Here, we examined circulating leptin levels in Black and White women with and without BC and characterized leptin-induced transcriptional changes in TNBC cell lines of White and Black racial backgrounds using RNA sequencing. Functional enrichment analyses were performed using Gene Ontology and KEGG pathway annotations, and clinical relevance was assessed using publicly available datasets. Circulating leptin levels were significantly elevated in women with BC and were relatively higher in Black than White women and associated with increased odds of luminal A and TNBC diagnoses. Leptin induced distinct transcriptional responses in two TNBC cell lines, with differential enrichment of oncogenic, metabolic, and signaling pathways, including spliceosome, steroid biosynthesis, PI3K-AKT, Notch, and extracellular matrix-receptor interaction. Several leptin-responsive genes showed concordant expression in clinical specimens and exhibited race- and subtype- associated differences and prognostic significance. Collectively, these findings identify distinct, context-dependent leptin-responsive transcriptional programs in TNBC and provide insight into their potential contributions to tumor heterogeneity and breast cancer disparities.
- Open Access
- 13 January 2015
- Published by Springer Nature in Breast Cancer Research
- Vol. 17 (1) , 5
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Introduction: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here we investigate the role of BRCA1-IRIS as a novel treatment target for TNBCs and their paclitaxel-resistant recurrences. Methods: We analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. We analyzed BRCA1-IRIS downstream signaling pathways in relation to paclitaxel treatment. We also analyzed a large cohort of breast tumor samples for BRCA1-IRIS, Forkhead box class O3a (FOXO3a) and survivin expression. Finally, we analyzed the effect of BRCA1-IRIS silencing or inactivation on TNBCs formation, maintenance and response to paclitaxel in an orthotopic model. Results: We show that low concentrations of paclitaxel triggers BRCA1-IRIS expression in vitro and in vivo, and that BRCA1-IRIS activates two autocrine signaling loops (epidermal growth factor (EGF)/EGF receptor 1 (EGFR)-EGF receptor 2 (ErbB2) and neurogulin 1 (NRG1)/ErbB2-EGF receptor 3 (ErbB3), which enhances protein kinase B (AKT) and thus survivin expression/activation through promoting FOXO3a degradation. This signaling pathway is intact in TNBCs endogenously overexpressing BRCA1-IRIS. These events trigger the intrinsic and acquired paclitaxel resistance phenotype known for BRCA1-IRIS-overexpressing TNBCs. Inactivating BRCA1-IRIS signaling using a novel inhibitory mimetic peptide inactivates these autocrine loops, AKT and survivin activity/expression, in part by restoring FOXO3a expression, and sensitizes TNBC cells to low paclitaxel concentrations in vitro and in vivo. Finally, we show BRCA1-IRIS and survivin overexpression is correlated with lack of FOXO3a expression in a large cohort of primary tumor samples, and that BRCA1-IRIS overexpression-induced signature is associated with decreased disease free survival in heavily treated estrogen receptor alpha-negative patients. Conclusions: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. These loops activate AKT, causing FOXO3a degradation and survivin overexpression. Taken together, this underscores the need for BRCA1-IRIS-specific therapy and strongly suggests that BRCA1-IRIS and/or signaling loops activated by it could be rational therapeutic targets for advanced TNBCs.
- 13 January 2015
- Published by Springer Nature in Breast Cancer Research
- Vol. 17 (1) , 5
Open AccessBRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Introduction: Intrinsic or acquired chemoresistance is a major problem in oncology. Although highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (TNBC) patients develop chemoresistance. Here we investigate the role of BRCA1-IRIS as a novel treatment target for TNBCs and their paclitaxel-resistant recurrences. Methods: We analyzed the response of BRCA1-IRIS overexpressing normal mammary cells or established TNBC cells silenced from BRCA1-IRIS to paclitaxel in vitro and in vivo. We analyzed BRCA1-IRIS downstream signaling pathways in relation to paclitaxel treatment. We also analyzed a large cohort of breast tumor samples for BRCA1-IRIS, Forkhead box class O3a (FOXO3a) and survivin expression. Finally, we analyzed the effect of BRCA1-IRIS silencing or inactivation on TNBCs formation, maintenance and response to paclitaxel in an orthotopic model. Results: We show that low concentrations of paclitaxel triggers BRCA1-IRIS expression in vitro and in vivo, and that BRCA1-IRIS activates two autocrine signaling loops (epidermal growth factor (EGF)/EGF receptor 1 (EGFR)-EGF receptor 2 (ErbB2) and neurogulin 1 (NRG1)/ErbB2-EGF receptor 3 (ErbB3), which enhances protein kinase B (AKT) and thus survivin expression/activation through promoting FOXO3a degradation. This signaling pathway is intact in TNBCs endogenously overexpressing BRCA1-IRIS. These events trigger the intrinsic and acquired paclitaxel resistance phenotype known for BRCA1-IRIS-overexpressing TNBCs. Inactivating BRCA1-IRIS signaling using a novel inhibitory mimetic peptide inactivates these autocrine loops, AKT and survivin activity/expression, in part by restoring FOXO3a expression, and sensitizes TNBC cells to low paclitaxel concentrations in vitro and in vivo. Finally, we show BRCA1-IRIS and survivin overexpression is correlated with lack of FOXO3a expression in a large cohort of primary tumor samples, and that BRCA1-IRIS overexpression-induced signature is associated with decreased disease free survival in heavily treated estrogen receptor alpha-negative patients. Conclusions: In addition to driving TNBC tumor formation, BRCA1-IRIS overexpression drives their intrinsic and acquired paclitaxel resistance, partly by activating autocrine signaling loops EGF/EGFR-ErbB2 and NRG1/ErbB2-ErbB3. These loops activate AKT, causing FOXO3a degradation and survivin overexpression. Taken together, this underscores the need for BRCA1-IRIS-specific therapy and strongly suggests that BRCA1-IRIS and/or signaling loops activated by it could be rational therapeutic targets for advanced TNBCs.